title: Thirteen-Week Study of PM014 Subchronic Oral Toxicity in Rats.
abstract: PM014 is a modified herbal formula based on Chung-Sang-Bo-Ha-Tang, which is a well-known prescription drug used for curing various inflammatory pulmonary diseases. We previously showed that PM014 attenuated lung inflammation in a murine model of chronic obstructive pulmonary disease (COPD). The objective of the present study was to evaluate the chronic oral toxicity of PM014 in rats. PM014 was administered to rats orally once daily at doses of 0, 750, 1500, and 3000 mg/kg/day for 13 weeks. The PM014 treatment did not result in any toxicologically significant changes between the control and treatment groups in body weight, clinical signs, food consumption, dermatological and serum biochemical parameters, organ weight ratio, or histopathology. We concluded that no PM014-related toxicity was detected even at the highest doses investigated in this repeated dose oral toxicity study. Based on our results, the no-observed-adverse-effect level (NOAEL) of PM014 was 3000 mg/kg/day in both genders. These results might provide supportive evidence of the safety of PM014 to develop a new drug.
authors.affiliation: Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1 Hoeki-Dong, Dongdaemoon-gu, Seoul 130-701, Republic of Korea.
authors.forename: Hwan-Suck
authors.identifier: 0000-0002-5901-0217
authors.initials: HS
authors.lastname: Chung
authors.affiliation: Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1 Hoeki-Dong, Dongdaemoon-gu, Seoul 130-701, Republic of Korea.
authors.forename: Hyunil
authors.initials: H
authors.lastname: Lee
authors.affiliation: Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1 Hoeki-Dong, Dongdaemoon-gu, Seoul 130-701, Republic of Korea.
authors.forename: Hyunsu
authors.initials: H
authors.lastname: Bae
references.citation: J Ethnopharmacol. 2004 Feb;90(2-3):415-9
references.pmid: 15013210
references.citation: Immunopharmacol Immunotoxicol. 2003 Nov;25(4):585-94
references.pmid: 14686800
references.citation: Evid Based Complement Alternat Med. 2013;2013:310989
references.pmid: 24171038
references.citation: Evid Based Complement Alternat Med. 2012;2012:837513
references.pmid: 22454687
references.citation: Toxicol Res. 2013 Jun;29(2):91-8
references.pmid: 24278634
references.citation: Neurosci Lett. 2013 Aug 9;549:63-8
references.pmid: 23791853
references.citation: Int Immunopharmacol. 2005 Feb;5(2):427-36
references.pmid: 15652771
references.citation: Exp Toxicol Pathol. 2006 Jan;57(3):213-9
references.pmid: 16343876
references.citation: J Appl Toxicol. 2014 Dec;34(12):1311-9
references.pmid: 24155209
references.citation: Toxicology. 2004 Oct 15;203(1-3):139-43
references.pmid: 15363589
references.citation: Phytochemistry. 2003 Aug;63(7):803-16
references.pmid: 12877922
references.citation: J Ethnopharmacol. 2014 Aug 8;155(1):113-22
references.pmid: 24879958
references.citation: BMC Complement Altern Med. 2009 Nov 15;9:43
references.pmid: 19912670
references.citation: Afr J Tradit Complement Altern Med. 2011;8(5 Suppl):220-5
references.pmid: 22754078
references.citation: Evid Based Complement Alternat Med. 2012;2012:769830
references.pmid: 22778777